Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer

NCT02568839 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

202

Enrollment

OTHER

Sponsor class

Conditions

Early-Stage Breast Carcinoma
HER-2 Positive Breast Cancer

Interventions

DRUG: docetaxel + trastuzumab sc + pertuzumab
DRUG: trastuzumab emtansin

Sponsor

Thomas Hatschek